SHG Provides Compensation Analysis to GB Sciences, Inc.
SHG is pleased to announce it has completed a detailed compensation analysis for GB Sciences, Inc., for the benefit of attracting and retaining the senior leadership team. Our analysis was used among management and its advisors.
About GB Sciences, Inc.
GB Sciences is a biopharmaceutical and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. To learn more about GB Sciences please visit Home - GB Sciences.
SHG's sell-side leaders, Cory Martin and Rai Archibold, share expert insights on how to prepare your business for sale, build value, and get the best outcome.
Matt Montague, an expert at SHG, shares insights on how buy side mergers and acquisitions can help growing companies expand and build long-term value.
